Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
John Buse, MD, PhD
Advertisement
Articles by John Buse, MD, PhD
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?
2
Online GLP-1 Sellers Often Skip Clinician Oversight
3
FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review
4
The Role of Politics in the AIDS Crisis: Perry N. Halkitis, PhD, MS, MPH
5